On Friday, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined -0.55% to $7.27.
ARIAD Pharmaceuticals, Inc. (ARIA) stated financial results for the second quarter of 2015, counting revenue from sales of Iclusig® (ponatinib). The Company also offered an update on key corporate initiatives and clinical-trial plans.
2015 Second Quarter Financial Results
Revenues
- Net product revenues from sales of Iclusig were $27.8 million for the quarter ended June 30, 2015, an enhance of 134% the second quarter of 2014 and 16% vs. the first quarter of 2015. These Iclusig product revenues are comprised of revenues of $21.6 million in the U.S. and $6.2 million in Europe. U.S. sales of Iclusig raised 16% from the first quarter to the second quarter of 2015, and European sales raised 19%.
- Shipments of Iclusig to patients in France were $2.5 million for the second quarter of 2015. Cumulative total shipments in France, taking into account the impact of foreign exchange, totaled $20.8 million through June 30, 2015. We will record revenue related to cumulative shipments in France upon completion of pricing and reimbursement negotiations in France, net of any amounts that will be refunded to the French health authorities as a result of such negotiations, which we anticipate will be accomplished in the fourth quarter of 2015.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Integrated Device Technology Inc (NASDAQ:IDTI)’s shares dropped -1.18% to $19.19.
Integrated Device Technology, Inc. (IDTI) declared that registration is open for the Double Racing Festival’s return to San Jose on Aug. 22. The centerpiece of the unique family-friendly festival is the Double Road Race 15K, which splits the race into two legs—a 10K and a 5K, with a break in between. The race was developed by Bob Anderson, founder of Runner’s World magazine.
The race starts and ends at the headquarters of IDT, the presenting sponsor of the San Jose event. Times from the two legs are combined for scoring.
The festival will feature live music and food. In addition to the Double Road Race, two additional racing events are planned at the festival. The UjENA Double 5K features a 3K leg and a 2K leg. Children 13 and younger can take part in the 1.5-mile Kids Cup Double, with a 1-mile leg followed by a half-mile leg. All races comprise a halftime. All Double Road Race finishers receive a medal, official race T-shirt, and a draw-string tote bag.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer. The Communications segment offers communication timing products, such as clocks and timing solutions; flow-control administration devices comprising Serial RapidIO switching solutions; multi-port products; telecommunications products; static random access memory products; first in and first out memories; digital logic products; radio frequency products; and MEMS oscillator solutions.
At the end of Friday’s trade, Allscripts Healthcare Solutions Inc (NASDAQ:MDRX)‘s shares dipped -0.91% to $14.08.
Allscripts Healthcare Solutions, Inc. (MDRX) declared its financial results for the three and six months ended June 30, 2015.
Second-Quarter and Six-Month Bookings Highlights:
Bookings(1) were $260 million, a second-quarter record, contrast with $233 million in the second quarter of 2014, an 11 percent enhance. A higher mix of new client sales across Allscripts portfolio, counting acute solutions in both international and domestic markets, ambulatory and payer life sciences solutions, drove second quarter 2015 bookings performance on a year-over-year basis.
About 65 percent of second-quarter bookings related to software delivery, while the remaining 35 percent related to sales of client services. This compares with 58 and 42 percent of bookings attributable to these revenue categories, respectively, in the second quarter of 2014. Software delivery bookings raised 25 percent in the second quarter, year-over-year.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services. The Clinical and Financial Solutions segment provides integrated clinical software applications, financial and information solutions, and related installation and maintenance services, counting EHR related software, financial and practice administration software, related installation and training services, and electronic claims administration services.
T-Mobile US Inc (NYSE:TMUS), ended its Friday’s trading session with -0.17% loss, and closed at $41.23.
T-Mobile US, Inc. (TMUS) declared that the quarterly dividend on its 5.50% Mandatory Convertible Preferred Stock (“Preferred Stock”) will be paid on September 15, 2015, to holders of record as of September 1, 2015. The dividend will be paid at a rate of $0.6875 per share of Preferred Stock.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smartphones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers. It offers services, devices, and accessories through its owned and operated retail stores, in addition to through its Websites. +
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
